ESC 25: NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency скачать в хорошем качестве

ESC 25: NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency

ESC Congress 2025 - NEWTON-CABG finds evolocumab with regular statin therapy did not improve vein graft patency after coronary artery bypass graft (CABG) surgery in the short-term. Dr Subodh Verma and Dr Lawrence Leiter (University of Toronto, Toronto, CA) join us to discuss findings from NEWTON-CABG CardioLink-5 (NCT03900026). The investigator-initiated multicenter, randomised, placebo-controlled study aimed to investigate the effect of evolocumab on saphenous vein graft patency within 21 d coronary artery bypass graft (CABG) surgery. Before randomisation to either evolocumab or placebo, post-operative patients will be on moderate or high intensity statin therapy. Findings showed that over 2 years, evolocumab produced a neutral result on vein graft patency after CABG surgery, However, evolocumab was found to lower LDL cholesterol by 60%. Interview Questions: What is the reasoning behind the NEWTON-CABG CardioLink-5 study? What was the study design and patient population? What were the key findings? How should these findings impact clinical practice? What further research is needed in this area? Recorded on-site at ESC Congress 2025, Madrid. Editors: Jordan Rance, Yazmin Sadik. Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh. Support: This is an independent interview produced by Radcliffe Cardiology. Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/ This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook:   / radcliffecardiology   Follow us on X: https://x.com/radcliffeCARDIO